Specific Receptors and Growth Effects of Insulin and Insulin-Like Growth Factors in a Human Cell Line Derived From Mixed Mesodermal Tumor of the Uterus

Abstract

Objective: Mixed mesodermal tumors of the uterus are highly malignant. The purpose of our present study was to investigate possible roles of insulin and insulin-like growth factors I and II (IGF-I and IGF-II) in the growth and development of these tumors.

Methods: Specific binding and growth effects of insulin, IGF-I, and IGF-II were studied in SK-UT-1 cells, derived from a human mixed mesodermal tumor of the uterus. The receptors were further characterized by competitive binding and chemical cross-linking studies.

Results: Binding studies with ¹²⁵I-insulin, ¹²⁵I-IGF-I, and ¹²⁵I-IGF-II revealed the presence of specific binding sites for these three growth factors. Specificity studies revealed that the binding sites for IGF-I and IGF-II are distinct. Binding of IGF-II was much higher than insulin and IGF-I binding. Scatchard analysis of the binding data revealed that the cell line has a higher number of IGF-II receptors (100,000 sites per cell) than insulin (1400 sites per cell) and IGF-1 (1200 sites per cell) receptors. The effect of these growth factors on cell growth was studied by monitoring the cell number and incorporation of [³H] thymidine into the DNA of the cells. Insulin-like growth factor-II was potent in stimulating the growth of these cells, but IGF-I did not have any effect. Insulin stimulated DNA synthesis only at pharmacologic concentrations.

Conclusion: These results indicate that IGF-II is mitogenic to mixed mesodermal tumors of the uterus. Insulin-like growth factor II may be involved in the growth regulation of mixed mesodermal tumors of the uterus.

Keywords

Mixed mesodermal tumors leiomyosarcoma IGF-II

Get full access to this article

View all access options for this article.

References

1. Norris HJ , Roth E . Taylor HB . Mesenchymal tumors of the uterus: II. A clinical and pathological study of 31 mixed mesodermal tumors. Obstet Gynecol 1966;28:57-63.

2. Sternberg WH , Clark WH , Smith RC . Malignant mixed müllerian tumor (mixed mesodermal tumor of the uterus): A study of twenty-one cases. Cancer 1954;7:704-724.

3. Silverberg SG . Malignant mixed mesodermal tumors of the uterus. An ultrastructural study. Am J Obstet Gynecol 1971;110:700-712.

4. Terada KY , Johnson TL , Hopkins M , Roberts JA . Clinicopathologic features of ovarian mixed mesodermal tumor and carcinosarcomas. Gynecol Oncol 1989;32:228-232.

5. Kinoshta M , Asano S , Yamashita M , Matsuda T . Mesodermal mixed tumor primary in the fallopian tube. Gynecol Oncol 1989;32:331-335.

6. Masuda A , Takeda A , Fukami H , Yamada C , Matsuyama M . Characteristics of cell lines established from a mixed mesodermal tumor of the ovary. Carcinomatous cells are changeable to sarcoma cells. Cancer 1987;60:2696-2703.

7. Laxman R , Currie JL , Kurman RJ , Dudzinski M , Griffin CA . Cytogenetic profile of uterine sarcomas. Cancer 1993;71:1283-1288.

8. Osborne KC , Bolar G , Monaco ME , Lippman ME . Hormone-responsive human breast cancer in long-term tissue culture. Cell Biology 1976;73:4536-4540.

9. Huff K , Knable , Lindsy R , et al. Multihormonal regulations of insulin-like growth factor-1 related protein in MCF-7 human breast cancer cells. Mol Endocrinol 1988;2:200-208.

10.

10. Daughaday WH , Rotwein A , Insulin-like growth factors I and II. Peptide messenger ribonucleic acid and gene structures, serum and tissue concentrations. Endocrinol Rev 1989;10:68-91.

11.

11. Clements DR . Structural and functional analysis of insulin-like growth factors. Br Med Bull 1989;45:465-480.

12.

12. DeChiara TM , Efstratiadis A , Robertson EJ . A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature 1990;345:78-80.

13.

13. Gray A , Tam AW , Dull TJ , et al. Tissue-specific and developmentally regulated transcription of the insulin-like growth factor 2 gene. DNA 1987;6:283-295.

14.

14. Han VK , D'Ercole AJ , Lund PK . Cellular localization of somatomedin (insulin-like growth factor) messenger RNA in the human fetus. Science 1987;236:193-197.

15.

15. Fogh J , Trempe G . New human tumor cell lines. In: Fogh J , ed. Human tumor cells in vitro. New York: Plenum Press, 1975.

16.

16. Freychet P , Roth J , Neville DM . Monoiodo insulin: Demonstration of its biologic activity and binding to fat cells and liver membranes. Biochem Biophys Res Commun 1971; 43:400-408.

17.

17. Stuart CA . Characteristics of a novel insulin receptor from stingray liver. J. Biol Chem 1988;263:7881-7886.

18.

18. Furlanetto RW , Dicardo JN . Somatomedin-C receptors and growth effects in human breast cancer cell maintained in long term tissue culture. Cancer Res 1984;44:2122-2128.

19.

19. Massague J , Czech M . The subunit structures of two distinct receptors for insulin-like growth fact-rI and II and their relationship to the insulin receptor. J Biol Chem 1982;257:5038-5045.

20.

20. Gloudemans T , Prinsen I , Van Unnik JAM , Lips CJM , Otter WD , Sussenback JS . Insulin-like growth factor gene expression in human smooth muscle tumors. Cancer Res 1990;50:6689-6695.

21.

21. Chandrasekhar Y , Heiner J , Osaumpke C , Nagamani M . Insulin-like growth factor I and II binding in human myometrium and leiomyomas. Am J Obstet Gynecol 1992;166:64-69.

22.

22. Guidice LC , Irvin JC , Drupin BA , et al. Insulin-like growth factor (IGF), IGF binding protein (IGF-BP) and IGF receptor gene expression and IGF BP synthesis in human uterine leiomyomata. Hum Reprod 1993;8:1796-1806.

23.

23. Vu TH , Vballe C , Bayanit S , Hoffman AR . Insulin-like growth factor II in uterine smooth muscle tumors: Maintenance of genomic imprinting in leiomyomata and loss of imprinting in leiomyosarcomata. J. Clin Endocrinol Metab 1995;80:1670-1676.

24.

24. Lupelescu AP . Effect of prolonged insulin treatment on carcinoma formation in mice. Cancer Res 1985;45:3288-3295.

25.

25. Nagamani M , Stuart CA , Dunhart PA , Doherty MG . Specific sites for insulin and insulin-like growth factor 1 in human endometrial cancer. Am J Obstet Gynecol 1991;165:1865-1871.

26.

26. Nagamani M , Stuart CA . Specific binding sites for insulin in the human myometrium and leiomyomas of the uterus. Fertil Steril 1992;58:120-123.

27.

27. Podczaski ES , Woomert CA , Stevens CW , et al. Management of mixed mesodermal tumors of the uterus. Gynecol Oncol 1989;32:240-244.

28.

28. Pagano G , Carsder M , Diana A , et al. Insulin resistance in the aged. The role of peripheral insulin receptors. Metabolism 1981;30:46-49.

29.

29. Fernanini E , Buzzigoli A , Bonnadonna R , et al. Insulin resistance in essential hypertension. N Eng J Med 1987;317:350-357.

30.

30. Montel R , Koss LG , Lewis JL , D'Anso JR . Mesodermal mixed tumors of the uterine corpus. Obstet Gynecol 1974;43:248-252.

31.

31. Miglietta L , Barreca A , Repetto L , Constantini M , Rosso R , Boccardo F . Suramins and serum insulin-like growth factor levels in metastatic cancer patients. Anticancer Research 1993;13:2473-2476.

32.

32. Minniti CP , Maggi M , Helman LJ . Suramin inhibits the growth of human rhabdomyosarcoma by interrupting the insulin-like growth factor 11 autocrine growth loop. Cancer Research 1992;52:1830-1835.

33.

33. Schrell UM , Gauer S , Kiesewetter F , et al. Inhibition of proliferation of human cerebral meningioma cells by suramin: Effects on cell growth, cell cycle phases, extracellular growth factors, and PDGF-BB autocrine loop. J Neurosurg 1995;82:600-607.

34.

34. Stein CA , LaRocca RV , Thomas R , McAfee N , Myers CE . Suramin: An anticancer drug with unique mechanism of action. J Clin Oncol 1989;17:499-508.